Clinical Trial Update: Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous RPR109881 in advanced breast cancer patients refractory to anthracycline, taxane, and capecitabine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• RPR109881

Snippet

Sponsor: Sanofi | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED